

**Remarks**

Claims 1-25 are pending.

Claims 3, 24 and 25 have been cancelled.

Claims 1, 11, 13-20, 22 and 23 have been previously presented.

Claim 2 has been amended to incorporate a limitation of Claim 1, the claim from which it depends. No new subject matter has been added.

Claims 4 and 7-9 have been amended to remove multiple dependency and are now presented in singularly dependent form. No new subject matter has been added.

Claim 10 has been amended to remove multiple dependency and correct a clear character error in a formula. No new subject matter has been added.

Claim 12 has been amended to correct a clear text error. No new subject matter has been added.

In view of the amendments and discussion, Examiner is requested to consider the application. Should it be helpful to expedite prosecution, the Examiner is encouraged to telephone.

Respectfully submitted,

/Mark A. Winter/

Mark A. Winter  
Agent for Applicants  
Registration No. 53,782  
Phone: 317-276-5362

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 16, 2007